UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Alexion Pharmaceuticals

In a report published earlier today, Canaccord Genuity reiterated its Buy rating for Alexion Pharmaceuticals

and raised its price target from $95.00 to $100.00. Canaccord said in their report “ALXN is seeing Soliris [the trade name for the monoclonal antibody Eculizumab] utilization split somewhat evenly between newly diagnosed patients and those with longer duration of disease (range of ages) treated by hematologists and nephrologists in the critical care and community settings. Uptake is being aided by initiatives focused on disease awareness, diagnosis, reimbursement and Soliris availability (Soliris can be delivered in 6-9 hours to ~85% of patients in the U.S.), particularly in the critical care setting where rapid diagnosis and treatment is essential.” Alexion Pharmaceuticals closed at $88.90 yesterday.